These findings indicate a shift in the broader heart failure management landscape, where treatment strategies are becoming more personalized, incorporating newer agents alongside beta-blockers and ACE inhibitors, offering a more nuanced approach to optimizing care in CHF patients. Here, ACE is linked to congestive heart failure.